Lieber Institute Fills Gap In Neuropsychiatric Research Ecosystem, Seeks Pharma Partnerships
This article was originally published in The Pink Sheet Daily
At a time of resurgent interest in CNS, The Lieber Institute for Brain Development’s capabilities and tissue resources set it apart from other brain research initiatives. The privately backed research lab is focused on translating genetic clues to the cause and course of schizophrenia and related disorders into new treatments.
You may also be interested in...
Precision Medicine In Psychiatry: Astellas Joins Search For Biomarkers, Drug Targets
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.